Home ›
Lymphoma Trials ›
NCT07587840
CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma
The purpose of this study is to determine the efficacy and safety of CD19/CD22 Chimeric Antigen Receptor (CAR) T-Cell immunotherapy as first-line consolidation therapy in patients with follicular lymphoma.
Trial Details
NCT ID NCT07587840
Phase PHASE2
Sponsor Liping Dou
Status RECRUITING
Cancer Type Lymphoma
Interventions CD22/CD19 CAR-T cell immunotherapy
Locations (sample) Beijing, Beijing Municipality, China|39.9075,116.39723
Key Eligibility Criteria
1\. With the patient's consent and signed informed consent form, willing and able to comply with the planned visits, research treatments, laborator… 2\. CD19 and/or CD22-positive follicular lymphoma (FL) confirmed by histology according to the WHO classification: The patient's disease is still evaluated as partial response (PR) after induction treatment with standard first-line chemotherapy regimen, or The patient's disease reaches complete response (CR) after induction treatment with standard first-line chemotherapy regimen, but there are high-ri…
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lymphoma Trials on Trialify →